Late CMV Disease and/or Recurrence in Renal Transplants Recipients with Prolonged Oral

Background/Aim: Oral ganciclovir effectively prevents CMV disease, but late-onset CMV disease is increasingly observed in pancreas-kidney and bone-marrow transplants recipients, specially with long-term prophylaxis. Then, the aim of this study was to verify if prolonged administration of oral ganciclovir prophylaxis could induce late CMV recurrence or disease in renal transplant recipients Material/Methods: 64 renal transplant recipients with a follow-up of 1 year were divided in two groups: 27 patients of short-term group (ST-group) treated 1-2 months with oral GCV prophylaxis, and 37 patients of large-term group (LT-group) treated 3-4 months. CMV Antigenemia and PCR were developed weekly until 4 first months after transplant, and monthly until the end of the study. Results: At 4 months, CMV replication was similar in ST-grou